07:50:57 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2024-10-31 Kvartalsrapport 2024-Q3
2024-08-08 Kvartalsrapport 2024-Q2
2024-04-25 Kvartalsrapport 2024-Q1
2024-04-05 X-dag ordinarie utdelning REG1V 0.38 EUR
2024-04-04 Årsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-10 Kvartalsrapport 2023-Q2
2023-04-27 Kvartalsrapport 2023-Q1
2023-03-24 X-dag ordinarie utdelning REG1V 0.36 EUR
2023-03-23 Årsstämma 2023
2023-02-09 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-04 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-11 X-dag ordinarie utdelning REG1V 0.34 EUR
2022-04-08 Årsstämma 2022
2022-02-10 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-05 Kvartalsrapport 2021-Q2
2021-04-23 Kvartalsrapport 2021-Q1
2021-03-18 X-dag ordinarie utdelning REG1V 0.32 EUR
2021-03-17 Årsstämma 2021
2021-02-11 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-06 Kvartalsrapport 2020-Q2
2020-06-09 X-dag ordinarie utdelning REG1V 0.30 EUR
2020-06-08 Årsstämma 2020
2020-04-22 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-04-16 Kvartalsrapport 2019-Q1
2019-03-21 X-dag ordinarie utdelning REG1V 0.28 EUR
2019-03-20 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-06 Kvartalsrapport 2018-Q2
2018-04-20 Kvartalsrapport 2018-Q1
2018-03-21 X-dag ordinarie utdelning REG1V 0.78 EUR
2018-03-20 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-07 Kvartalsrapport 2017-Q2
2017-05-22 Årsstämma 2017
2017-04-20 Kvartalsrapport 2017-Q1
2017-03-23 X-dag ordinarie utdelning REG1V 0.74 EUR
2017-02-16 Bokslutskommuniké 2016
2016-10-31 Kvartalsrapport 2016-Q3
2016-08-08 Kvartalsrapport 2016-Q2
2016-04-25 Kvartalsrapport 2016-Q1
2016-03-16 X-dag ordinarie utdelning REG1V 0.70 EUR
2016-03-15 Årsstämma 2016
2016-02-15 Bokslutskommuniké 2015
2015-10-27 Kvartalsrapport 2015-Q3
2015-08-10 Kvartalsrapport 2015-Q2
2015-04-24 Kvartalsrapport 2015-Q1
2015-03-20 X-dag ordinarie utdelning REG1V 0.45 EUR
2015-03-19 Årsstämma 2015
2015-02-12 Bokslutskommuniké 2014
2014-10-21 Kvartalsrapport 2014-Q3
2014-08-04 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-03-21 X-dag ordinarie utdelning REG1V 0.30 EUR
2014-03-20 Årsstämma 2014
2014-02-12 Bokslutskommuniké 2013
2013-12-11 X-dag bonusutdelning REG1V 0.3
2013-12-09 Extra Bolagsstämma 2013
2013-10-22 Kvartalsrapport 2013-Q3
2013-08-28 Kapitalmarknadsdag 2013
2013-08-05 Kvartalsrapport 2013-Q2
2013-08-02 X-dag bonusutdelning REG1V 0.12
2013-04-19 Kvartalsrapport 2013-Q1
2013-03-28 Split REG1V 10:1
2013-03-22 X-dag ordinarie utdelning REG1V 0.02 EUR
2013-03-21 Årsstämma 2013
2013-02-08 Bokslutskommuniké 2012
2012-10-19 Kvartalsrapport 2012-Q3
2012-08-06 Kvartalsrapport 2012-Q2
2012-04-19 Kvartalsrapport 2012-Q1
2012-03-29 X-dag ordinarie utdelning REG1V 0.02 EUR
2012-03-28 Årsstämma 2012
2012-02-16 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-08 Kvartalsrapport 2011-Q2
2011-04-27 Kvartalsrapport 2011-Q1
2011-04-01 X-dag ordinarie utdelning REG1V 0.02 EUR
2011-03-31 Årsstämma 2011
2011-02-16 Bokslutskommuniké 2010
2010-04-09 X-dag ordinarie utdelning REG1V 0.01 EUR
2009-04-16 X-dag ordinarie utdelning REG1V 0.02 EUR
2008-04-03 X-dag ordinarie utdelning REG1V 0.04 EUR
2007-04-09 X-dag ordinarie utdelning REG1V 0.01 EUR
2006-03-31 X-dag ordinarie utdelning REG1V 0.00 EUR
2005-04-01 X-dag ordinarie utdelning REG1V 0.00 EUR
2004-03-29 X-dag ordinarie utdelning REG1V 0.00 EUR
2003-03-24 X-dag ordinarie utdelning REG1V 0.00 EUR
2002-04-15 X-dag ordinarie utdelning REG1V 0.00 EUR


ListaLarge Cap Helsinki
Revenio är verksamt inom medicinteknik. Inom koncernen återfinns forskning och utveckling av tryckmätningsteknik som används vid behandling av ett flertal sjukdomar såsom glaukom, osteoporos, hudcancer samt astma. Verksamhet innehas på global nivå och drivs via flertalet dotterbolag med vardera affärsinriktning. Bolagets huvudkontor ligger i Vantaa.
2023-08-10 08:10:00

Revenio Group Corporation, Stock Exchange Release, August 10, 2023 at 9.10 a.m. (EEST)

The Board of Directors of Revenio Group Corporation has decided on a new three-year performance period of the long-term performance-based share plan for the company’s Leadership Team and other key personnel. Long-term performance-based share plans are part of the company's key personnel reward program and their goal is to support the implementation of the company's strategy and to align the objectives of key employees and the company's shareholders in order to increase the value of the company.

A long-term performance-based share plan for 2023-2025
The new three-year performance period of the share plan covers the years 2023-2025. The Board of Directors decides separately the minimum, target and maximum rewards for each participant, as well as the performance criteria and related targets. The amount of the reward paid to participants depends on achieving the pre-established targets. No reward will be paid if targets are not met or if the participant’s employment or service ends before the reward payment. The targets for the plan relate to the company’s three-year total shareholder return and cumulative operating profit.

If the targets of the plan are reached, rewards will be paid to participants in the spring of 2026 after the end of the performance period. The rewards according to the share plan are calculated in shares. The maximum number of shares to be paid based on the performance period is at most 34,115 Revenio Group Corporation’s shares. This number of shares represents gross earnings, from which the portion required to cover the taxes arising from the share plan and other possible applicable tax-related payments is deducted, which is paid in cash. In practice, about 40% of the total number of shares is paid in shares and about 60% in cash to cover taxes and other possible tax-related payments. However, the company has the right to pay the reward fully in cash under certain circumstances.

Revenio Group Corporation
Board of Directors

For further information, please contact
Robin Pulkkinen, CFO, tel. +358 50 505 9932

Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media

Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2022, the Group’s net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.